Merck KGaA Says It Plans One New Drug Launch Every One and a Half Years
21 Novembro 2022 - 10:03AM
Dow Jones News
By Cecilia Butini
Merck KGaA said Monday that it plans to introduce one new
healthcare product every one and a half years as it seeks to double
research and development in oncology, neurology and immunology.
The German healthcare and technology company said more than 50%
of future launches will result from co-development partnerships
with external companies and in-licensing of assets.
The next wave of launches are expected to come from phase-3
trials of head-and-neck cancer medicine xevinapant and evobrutinib,
a potential treatment for relapsing multiple sclerosis, the company
said.
Merck's expected new launches could be either for new drugs or
for new uses of existing drugs, it said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
November 21, 2022 07:48 ET (12:48 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Merck KGAA (TG:MRK)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Merck KGAA (TG:MRK)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
